세계 흑색종 치료제 시장 규모는 2023년 74억 달러에서 예측 기간 동안 10.2%의 CAGR을 기록하며 2028년 121억 달러 규모로 성장할 것으로 예상됩니다.
지역별로 살펴보면, 북미 시장은 2023년 35억 달러에서 2028년 58억 달러 규모로 성장해 연평균 11.0%의 성장률을 기록할 것으로 예상됩니다. 유럽 시장은 2023년 23억 달러에서 연평균 10.1% 성장해 2028년 38억 달러 규모로 성장할 것으로 예상됩니다.
세계 흑색종 치료제 시장을 조사했으며, 시장 및 기술 개요, 시장 영향요인 및 시장 기회 분석, 시장 규모 추이 및 예측, 각 부문별·지역별 상세 분석, 기술 및 특허 동향, 파이프라인 분석, ESG 전개, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.
목차
제1장 서론
제2장 요약과 하이라이트
제3장 시장 및 기술 배경
- 위험인자·원인·예방
- 증상
- 병태생리·임상 아류형
- 예후
- 역학
- 진단
- 생검
- 임상 검사
- 혈액 검사
- 영상 검사
- 치료
- 면역요법
- PD-1 및 PD-L1 억제제
- CTLA-4 억제제
- LAG-3 억제제
- 인터류킨-2(IL-2, 프로류킨)
- 바이러스 요법
- BRAF 억제제
- MEK 억제제
제4장 시장 역학
- 시장 요인
- 시장 성장 촉진요인
- 흑색종 유병률 증가
- 기술 진보와 제품 발매
- 전략적 대처
- 조기 발견 툴의 개발
- 환자 옹호 단체와 의식 향상
- 시장 성장 억제요인
- 고액의 치료비
- 엄격한 규제
- 치료에 대한 내성
- 시장 기회
제5장 시장 내역 : 유형별
- 개요
- 수술
- 광범위 절제
- 모스 수술
- 절단
- 림프절 절제술
- 치료법
- 치료법 : 유형별
- 방사선 치료
제6장 시장 내역 : 질환 스테이지별
제7장 시장 내역 : 지역별
제8장 지속가능성 : ESG 관점
- 제약 업계의 ESG 과제
- 흑색종 치료제 시장의 ESG 관행
- 환경에 대한 대처
- 사회에 대한 대처
- 거버넌스에 대한 대처
- 사례 연구
- BCC에 의한 견해
제9장 신기술/개발
- 신규 면역관문억제제
- 양자 세포 치료
- Engineered TCR 요법
- 백신
- 표적요법
제10장 규제 상황·파이프라인 분석
제11장 특허 분석
제12장 경쟁 상황
제13장 기업 개요
- AMGEN INC.
- ASTRAZENECA PLC
- BRISTOL-MYERS SQUIBB
- ERASCA INC.
- F. HOFFMANN-LA ROCHE AG
- HUYABIO INTERNATIONAL
- IOVANCE BIOTHERAPEUTICS INC.
- IO BIOTECH
- MERCK & CO. INC.
- MODERNA INC.
- NOVARTIS AG
- PFIZER INC.
- REGENERON PHARMACEUTICALS INC.
ksm
Highlights:
The global market for melanoma therapeutics is estimated to increase from $7.4 billion in 2023 to reach $12.1 billion by 2028, at a compound annual growth rate (CAGR) of 10.2% from 2023 through 2028.
North American market for melanoma therapeutics is estimated to increase from $3.5 billion in 2023 to reach $5.8 billion by 2028, at a compound annual growth rate (CAGR) of 11.0% from 2023 through 2028.
European market for melanoma therapeutics is estimated to increase from $2.3 billion in 2023 to reach $3.8 billion by 2028, at a compound annual growth rate (CAGR) of 10.1% from 2023 through 2028.
Report Scope:
This study investigates the melanoma treatment market. BCC Research analyzes melanoma treatment based on treatment type, cancer stage and type of therapeutics. BCC determines the current market status in each segment, examines its impact on future needs and presents growth forecasts over the next five years. The report provides a detailed analysis of the market's drivers, challenges, and opportunities. The report also covers market projections through 2028 and analyzes market share for key market players. In its profiles of key companies, the report provides detailed information about their business segments, financials, product portfolios and recent developments. The report also discusses the market impact of the COVID-19 pandemic, emerging technologies, and new developments, ESG development and investment outlook.
Report Includes:
- 30 data tables and 18 additional tables
- An overview of the global market for melanoma treatment
- Analyses of global market trends, with data from 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
- Description of various treatment options such as chemotherapy, surgical resection, immunotherapy, and targeted therapies; and various treatment approaches for the betterment of patient's overall health
- A look at the advancements in the genetic profiling of melanocytes and identification of novel molecules that involved in melanoma's development
- Information on new potential therapeutic target discovery; and description of novel immune checkpoint inhibitors, adoptive cell therapy and engineered TCR therapy
- Coverage of innovation, technological advancements, and the launch of novel products from market players
- Detailed analysis of the regulatory framework and policies and product pipeline of the industry, and discussion on ESG challenges in the pharmaceutical industry and ESG practices in the melanoma treatment market
- Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies and a relevant patent analysis
- Comprehensive company profiles of the leading players of the industry, including Amgen, Roche, Merck & Co., Pfizer Inc., BMS, and Novartis AG
Table of Contents
Chapter 1 Introduction
- Study Goals and Objectives
- Scope of the Report
- Reasons for Doing the Study
- Methodology
- Information Sources
- Geographic Breakdown
- Segmentation Breakdown
Chapter 2 Summary and Highlights
- Market Outlook
- Market Summary
Chapter 3 Market and Technology Background
- Introduction
- Risk Factors, Causes and Prevention
- Symptoms
- Pathophysiology and Clinical Subtypes
- Prognosis
- Epidemiology
- Diagnosis
- Biopsy
- Laboratory Tests
- Blood Tests
- Imaging Tests
- Treatment
- Immunotherapy
- PD-1 and PD-L1 Inhibitors
- CTLA-4 inhibitors
- LAG-3 Inhibitors
- Interleukin-2 (IL-2, Proleukin)
- Virus Therapy
- BRAF inhibitors:
- MEK Inhibitors
Chapter 4 Market Dynamics
- Market Factors
- Market Drivers
- Increasing Prevalence of Melanoma
- Technological Advancements and Product Launches
- Strategic Initiatives
- Developments in Early Detection Tools
- Patient Advocacy Groups and Awareness
- Market Restraints
- High Cost of Treatment
- Stringent Regulations
- Resistance to Therapies
- Market Opportunities
Chapter 5 Market Breakdown by Type
- Overview
- Surgery
- Wide Excision
- Mohs Surgery
- Amputation
- Lymph Node Dissection
- Therapeutics
- Therapeutics by Type
- Radiation Therapy
Chapter 6 Market Breakdown by Disease Stage
- Overview
- Localized Disease
- Regional Disease
- Distant Disease
Chapter 7 Market Breakdown by Region
- Overview
- North America
- Europe
- Asia-Pacific
- Rest of the World
Chapter 8 Sustainability: An ESG Perspective
- Introduction
- ESG Challenges in the Pharmaceutical Industry
- ESG Practices in the Market for Melanoma Therapeutics
- Environmental Initiatives
- Social Initiatives
- Governance Initiatives
- Case Study
- BCC Research Viewpoint
Chapter 9 Emerging Technologies/ Developments
- Introduction
- Novel Immune Checkpoint Inhibitors
- Adoptive Cell Therapy
- Engineered TCR Therapy
- Vaccines
- Targeted Therapy
Chapter 10 Regulatory Landscape and Pipeline Analysis
- Regulatory Landscape
- United States
- Europe
- Japan
- Pipeline Analysis
Chapter 11 Patent Analysis
- Patent Review by Year
- Patent Review by Country
- Patent Review
Chapter 12 Competitive Landscape
- Mergers and Acquisitions
- Strategic Initiatives
- Competitive Analysis
Chapter 13 Company Profiles
- AMGEN INC.
- ASTRAZENECA PLC
- BRISTOL-MYERS SQUIBB
- ERASCA INC.
- F. HOFFMANN-LA ROCHE AG
- HUYABIO INTERNATIONAL
- IOVANCE BIOTHERAPEUTICS INC.
- IO BIOTECH
- MERCK & CO. INC.
- MODERNA INC.
- NOVARTIS AG
- PFIZER INC.
- REGENERON PHARMACEUTICALS INC.
